Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Bickerstaff brainstem encephalitis Indication Strategy Report 2026: C5, Trials and Deals
30 July 2026
2026 Bickerstaff brainstem encephalitis indication strategy covering epidemiology, C5 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Hashimoto encephalopathy Indication Strategy Report 2026: CD20, Trials and Deals
30 July 2026
2026 Hashimoto encephalopathy indication strategy covering epidemiology, CD20 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
IgG4-related aortitis Indication Strategy Report 2026: CD20, Trials and Deals
30 July 2026
2026 IgG4-related aortitis indication strategy covering epidemiology, CD20 biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Acute hemorrhagic leukoencephalitis Indication Strategy Report 2026: IL-6, Trials and Deals
30 July 2026
2026 Acute hemorrhagic leukoencephalitis indication strategy covering epidemiology, IL-6 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Amyloid beta-related angiitis Indication Strategy Report 2026: CD20, Trials and Deals
30 July 2026
2026 Amyloid beta-related angiitis indication strategy covering epidemiology, CD20 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Cerebral amyloid angiopathy-related inflammation Indication Strategy Report 2026: CD20, Trials and Deals
30 July 2026
2026 Cerebral amyloid angiopathy-related inflammation indication strategy covering epidemiology, CD20 biology, active trials, transactions, unmet need,…
Latest Hotspot
8 min read
IgG4-related pancreatitis Indication Strategy Report 2026: CD20, Trials and Deals
30 July 2026
2026 IgG4-related pancreatitis indication strategy covering epidemiology, CD20 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
IgG4-related kidney disease Indication Strategy Report 2026: CD20, Trials and Deals
30 July 2026
2026 IgG4-related kidney disease indication strategy covering epidemiology, CD20 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
IgG4-related sialadenitis Indication Strategy Report 2026: CD20, Trials and Deals
30 July 2026
2026 IgG4-related sialadenitis indication strategy covering epidemiology, CD20 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
IgG4-related ophthalmic disease Indication Strategy Report 2026: CD20, Trials and Deals
30 July 2026
2026 IgG4-related ophthalmic disease indication strategy covering epidemiology, CD20 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Idiopathic hypertrophic pachymeningitis Indication Strategy Report 2026: CD20, Trials and Deals
30 July 2026
2026 Idiopathic hypertrophic pachymeningitis indication strategy covering epidemiology, CD20 biology, active trials, transactions, unmet need, competition and…
Latest Hotspot
8 min read
Retroperitoneal fibrosis Indication Strategy Report 2026: CD20, Trials and Deals
30 July 2026
2026 Retroperitoneal fibrosis indication strategy covering epidemiology, CD20 biology, active trials, transactions, unmet need, competition and market…